Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1032
INCLUSION Global Study Details
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries.
Prevention Option:
Long-Acting PrEP Generic License Coverage
This map shows country coverage under current voluntary licensing agreements for generic versions of three long-acting PrEP products: alimatravir (ALI), cabotegravir (CAB) and lenacapavir (LEN). The graphic reflects publicly announced licenses and does not indicate product registration, availability or access within countries. For more information, visit the PrEPWatch Long-Acting PrEP Status page.
Prevention Option:
Accelerating policy approval and uptake of the dual prevention pill in Zambia through early stakeholder engagement
The Dual Prevention Pill (DPP), a combination of PrEP and combined oral contraception (COC), offers a novel, female-controlled option for HIV and unintended pregnancy prevention. This article in AIDS Care, authored by AVAC Fellow Rhoda Msiska, AVAC staff members Kate Segal and Cindra Feuer, and Newton Donkola, demonstrates how early, multisectoral stakeholder engagement could accelerate DPP approval and adoption in Zambia.
AVAC Infographics for AIDS 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
Letter of Support for Dr. Anthony S. Fauci
In support of Dr. Anthony Fauci, AVAC submitted a letter to the Committee on Homeland Security
and Governmental Affairs ahead of a Congressional hearing focused on the origins of COVID-19. This letter reiterates Dr. Fauci’s decades-long dedication to understanding the immunology and virology of HIV and outlines AVAC’s grave concerns that the continued politicization of science and targeted subpoenaing of public servants like Dr. Fauci will have a chilling effect on public health and research.
The Persistence Paradigm: Ensuring the Longevity of Health Equity Research
In these exceptional times, how is health equity research faring? What can we collaboratively do to sustain and continue this important work which is so critical to supporting healthy communities and an HIV response? How can academia and community...
Alimatravir (MK-8527) Licensing Timeline
This timeline demonstrates the speed of generic licensing for alimatravir (MK-8527) compared to lenacapavir (LEN) and cabotegravir (CAB).
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of July 2026.
Prevention Option:
Injectable PrEP Regulatory Approvals
This graphic tracks regulatory approvals for injectable Cabotegravir and Lenacapavir for PrEP as of July 2026.
showing 1-10 of 1032